Abstract: Lighting arrangements for monitoring utility flow and methods for monitoring utility flow are provided. In one example, the lighting arrangement includes a smart utility monitoring system that is configured to measure output data from a utility device and process the output data into utility flow data. A controller is configured to retrieve the utility flow data from the smart utility monitoring system. A plurality of lights is in communication with the controller. The controller is configured to direct the plurality of lights to display a light pattern in which at least a portion of the light pattern corresponds to the utility flow data.

Abstract: A light-emitting module (100) is disclosed, the light-emitting module comprising a first light-emitting diode, LED, array (104) arranged on a substrate (102). The first LED array has a first perimeter (106) and comprises a plurality of first LEDs (108) configured to emit first light. The light-emitting module further comprises a second LED array (110) arranged on the substrate. The second LED array has a second perimeter (112), smaller than the first perimeter and comprises a plurality of second LEDs (114) configured to emit second light. The second LED array is arranged off-center within the first LED array. Further, the light-emitting module comprises a controller (116) configured to individually control the first LED array and the second LED array.

Abstract: The present invention relates, in part, to chimeric proteins that bind a non-cellular structure and their use as therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the chimeric proteins and their use in the treatment of various diseases.

Abstract: There is described a computer-implemented method for measurement of a level of pain. The method comprises the steps of: — receiving measured data comprising electroencephalogram, EEG, data collected from one or more EEG electrodes; — extracting from the EEG data, a group 4 indicator corresponding to: — a power, power (ta), associated with a theta-alpha frequency band, ta, within a theta-alpha frequency range; and - determining, based on said group 4 indicator, a level of pain, LoP, which is a value indicative for the level of pain in the subject.

Abstract: There is described a computer-implemented method for measurement of a level of modified consciousness and a level of pain. The method comprises the steps of: - receiving measured data comprising electroencephalogram, EEG, data collected from one or more EEG electrodes; - extracting from the EEG data, a group indicators corresponding to: - a power, power (ta), associated with a theta-alpha frequency band, ta, within a theta-alpha frequency range; and - a power, F-power(dt) and/or P-power(dt), associated with a delta-theta frequency band, dt, within a delta-theta frequency range extracted from the at least one F- EEG and/or P- EEG electrode data; - determining, based on said group indicators, a depth of state, DoS, which is a value indicative for the level of a modified state of consciousness and a level of pain, LoP, which is a value indicative for the level of pain in the subject.

Abstract: The present invention relates, in part, to targeted chimeric proteins with beneficial therapeutic effects, including, for example, effects mediated by mutant forms of soluble agents that are part of the chimeric proteins. Pharmaceutical compositions comprising the chimeric proteins are also provided. The present invention finds use in the treatment of various disease and disorders.

Abstract: The present invention relates, in part, to chimeric proteins that bind a non-cellular structure and their use as therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the chimeric proteins and their use in the treatment of various diseases.

Abstract: There is described a computer-implemented method for measurement of a level of anxiety combined with and/or correlated with a level of a modified state of consciousness and/or a level of pain. There is received measured data comprising BEG data. From the EEG data there is extracted a group (8) indicator based on a power, P-power (dt), associated with a delta-theta frequency band, dt, within a delta-theta frequency range. From the EEG data there is further extracted a group (1) indicator based on, a power, F-power(dt), associated with a delta-theta frequency band, dt, within a delta-theta frequency range; and/or a group (4) indicator corresponding to a power, power (ta), associated with a theta-alpha frequency band, ta, within a theta-alpha frequency range. There is e determined, based on said group (8) indicator, a level of anxiety.

Abstract: There is described a method and system for measuring a level of anxiety. Measured data comprising EEG data collected from a parietal (P) EEG electrode is received. A group 8 indicator based on a power, P-power (dt), associated with a delta-theta frequency band, dt, within a delta-theta frequency range is extracted. Based on said group 8 indicator, a level of anxiety, LoA, is determined which is a value indicative of the level of anxiety of the subject.

Abstract: The present invention relates, in part, to targeted chimeric proteins with beneficial therapeutic effects, including, for example, effects mediated by mutant forms of soluble agents that are part of the chimeric proteins. Pharmaceutical compositions comprising the chimeric proteins are also provided. The present invention finds use in the treatment of various disease and disorders.

Abstract: The present invention relates to methods of treating or preventing chewing lice infestations of ruminant animals by subcutaneously administering an isoxazoline compound of formula (I).

Abstract: Systems, methods, and computer-readable media for determining at least one valid mood for a collection of media content items of a media library are provided.

Abstract: A decanter centrifuge includes a centrifugal bowl rotatable around a preferably horizontal axis of rotation including at least one liquid phase discharge outlet at one end and at least one solids discharge opening at the other end, a scroll conveyor mounted substantially concentrically inside the bowl for rotation about the axis of rotation of the centrifugal bowl at a slightly different speed relative to the bowl for transporting the solid phase towards the solids discharge opening. The liquid phase discharge is enabled through port members. A set of bushings for solid discharge is provided to adjust the solid discharge diameter inside the bowl. With these bushings optimal cake discharge may be achieved.

Abstract: The present invention relates, in part, to chimeric protein or chimeric protein complex comprising a CD13 targeting moiety and a signaling agent (e.g., without limitation TNF or IFN-?) and methods of treatment using such compositions.

Abstract: The present invention relates to methods of treating or preventing arthropod infestations of poultry animals and methods of controlling arthropod infestations in poultry animal's environment by administering an isoxazoline compound of formula (I) via drinking water.

Abstract: The present invention relates to methods of treating or preventing arthropod infestations of poultry animals and methods of controlling arthropod infestations in poultry animal's environment by administering an isoxazoline compound of formula (I) via drinking water.